Evaluating the efficacy of compound MP-001 in survival, motor function and muscular markers in SOD1G93A mice
We also investigated on SOD1G93A mice the therapeutic potential of the compound MP-001 (Fig. 5A), characterized by limited or negligible CNS availability (Fig. 1), thereby confining its mechanism of action to peripheral tissues. The body weight of all animals was monitored weekly from 8 weeks of age until 22 weeks. We observed reduced weight loss in the treated animals, with significant differences at the 13th and 15th weeks of age (Fig. 5B). However, as depicted in the survival analysis, MP-001 treatment did not significantly extend the survival of SOD1G93A mice (Fig. 5C). Regarding the results obtained in the motor tests, no discernible improvement was observed in the SOD1G93A mice treated with MP-001 (Figure 5D,E).